BNN Bloomberg EN

NetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data

NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a company developing advanced artificial intelligence solutions for clinical trial optimization and precision medicine for the pharmaceutical industry, today announced that it signed a new contract with a leading global biopharmaceutical company developing innovative treatments for psychiatric and neurological disorders. The agreement will allow NetraMark to analyze data from this client’s Phase 2 clinical trial for depression.

Mar 11, 2026 &03221111202631; 16:22 UTC www.bnnbloomberg.ca Trending 4/5

Read original on www.bnnbloomberg.ca ↗

↗

Positive for markets

Sentiment score: +75/100

Moderate impact Short-term (days)

WHAT THIS MEANS

NetraMark Holdings secured a new contract with a major global biopharmaceutical company to analyze Phase 2 depression trial data, demonstrating continued demand for its AI-powered clinical trial optimization solutions. This contract win validates NetraMark's technology platform and expands its revenue pipeline in the high-value pharmaceutical analytics sector.

AI CONFIDENCE

78% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

AIAI

AIAIStock

Expected to rise

New contract win with major biopharmaceutical client validates AI platform and signals revenue growth; positive for TSX-listed biotech AI company

↑

AINMF

AINMFStock

Expected to rise

OTC listing benefits from same contract announcement; increased visibility and revenue prospects

↑

PF0

PF0Stock

Expected to rise

Frankfurt listing exposure to same positive catalyst; European investors gain access to growth story

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Consider accumulating AIAI/AINMF positions on this positive catalyst; monitor for additional contract announcements and Phase 2 trial progress updates. Watch for quarterly earnings impact and guidance revisions reflecting new revenue streams.

KEY SIGNALS

New enterprise contract with tier-1 biopharmaceutical clientPhase 2 trial data analysis demonstrates clinical relevance of AI platformRevenue diversification and pipeline expansionValidation of AI-driven clinical trial optimization technologyPsychiatric/neurological disorder focus area shows market traction

SECTORS INVOLVED

BiotechnologyArtificial IntelligencePharmaceuticalsHealthcare Technology

Analysis generated on Mar 12, 2026 at 00:48 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by BNN Bloomberg. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

NetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data

RELATED INTELLIGENCE